MINUTOLO, FILIPPO
 Distribuzione geografica
Continente #
NA - Nord America 14.486
EU - Europa 8.337
AS - Asia 2.439
AF - Africa 172
SA - Sud America 36
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 3
Totale 25.501
Nazione #
US - Stati Uniti d'America 14.005
IT - Italia 3.945
CN - Cina 1.255
SE - Svezia 1.132
DE - Germania 786
BG - Bulgaria 725
CA - Canada 476
TR - Turchia 412
GB - Regno Unito 346
UA - Ucraina 300
VN - Vietnam 286
FI - Finlandia 236
AT - Austria 204
FR - Francia 186
IN - India 164
BE - Belgio 148
CH - Svizzera 137
SG - Singapore 105
HK - Hong Kong 92
RU - Federazione Russa 77
NG - Nigeria 67
CI - Costa d'Avorio 64
JP - Giappone 47
SN - Senegal 30
NL - Olanda 27
AU - Australia 20
BR - Brasile 19
IR - Iran 19
PL - Polonia 17
GR - Grecia 14
DK - Danimarca 10
ES - Italia 10
KR - Corea 10
TW - Taiwan 9
IE - Irlanda 8
MO - Macao, regione amministrativa speciale della Cina 8
NZ - Nuova Zelanda 8
RO - Romania 8
CL - Cile 6
EC - Ecuador 5
EG - Egitto 5
ID - Indonesia 5
DZ - Algeria 4
RS - Serbia 4
UZ - Uzbekistan 4
CO - Colombia 3
EU - Europa 3
HU - Ungheria 3
IL - Israele 3
LK - Sri Lanka 3
MX - Messico 3
TH - Thailandia 3
AM - Armenia 2
CZ - Repubblica Ceca 2
JO - Giordania 2
KW - Kuwait 2
LU - Lussemburgo 2
PK - Pakistan 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
AL - Albania 1
AR - Argentina 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
LI - Liechtenstein 1
MY - Malesia 1
NO - Norvegia 1
OM - Oman 1
SA - Arabia Saudita 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 25.501
Città #
Woodbridge 2.088
Ann Arbor 1.419
Fairfield 1.362
Chandler 1.349
Houston 1.230
Serra 1.210
Milan 969
Ashburn 789
Sofia 725
Seattle 546
Wilmington 505
Cambridge 481
Ottawa 451
Beijing 444
New York 424
Jacksonville 397
Izmir 391
Princeton 322
Lawrence 275
Nanjing 259
Medford 255
Vienna 154
Des Moines 147
Dearborn 146
Dong Ket 136
Bern 122
Brussels 121
Rome 120
Redwood City 119
Marseille 111
Boulder 110
Nanchang 109
Florence 97
London 93
Hong Kong 87
Pisa 85
San Diego 79
Lagos 67
Abidjan 64
Jüchen 60
Hebei 46
Kunming 45
Shenyang 45
Pune 40
Nürnberg 37
Washington 37
Norwalk 35
Jiaxing 33
Tianjin 33
Boardman 31
Dakar 30
Hefei 29
Auburn Hills 28
Hangzhou 27
Mumbai 27
Guangzhou 26
Livorno 26
Changsha 24
Bologna 23
Frankfurt am Main 22
Jinan 22
Louvain-la-Neuve 21
Shanghai 20
San Francisco 18
Orange 17
Tokyo 17
Pistoia 16
Los Angeles 15
Falls Church 14
Phoenix 14
Caserta 12
Toronto 12
Massa 11
Carrara 10
Indiana 10
Palermo 10
Piombino 10
Alessandria 9
Altopascio 9
Bathinda 9
Chengdu 9
Dallas 9
Lucca 9
South Bend 9
Taipei 9
Zurich 9
Changchun 8
Frisco 8
Hyderabad 8
Macao 8
Pieve Fosciana 8
Tappahannock 8
Viareggio 8
Warsaw 8
Zhengzhou 8
Alassio 7
Costa Mesa 7
Fremont 7
Leawood 7
Massarosa 7
Totale 18.999
Nome #
COMPOSTO INIBITORE DELL’ENZIMA LATTATO DEIDROGENASI (LDH) E COMPOSIZIONE FARMACEUTICA CHE COMPRENDE TALE COMPOSTO 230
4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors 228
GLUT1 and LOX inhibitors as perspective anticancer agents tackling glucose avidity and ECM remodeling in tumors 192
Receptor-based virtual screening evaluation for the identification of estrogen receptor β ligands 184
Synthesis and biological evaluation of non-glucose glycoconjugated N-hydroyxindole class LDH inhibitors as anticancer agents 178
Phenylpropanoids and flavonoids from Phlomis kurdica as inhibitors of human lactate dehydrogenase. 176
Nuovi attivatori dell’enzima SIRT1 per il trattamento delle patologie cardiovascolari e cardiometaboliche 168
Identification of Lactate Dehydrogenase 5 Inhibitors using Pharmacophore- Driven Consensus Docking 163
Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors 157
New NO-Releasing Pharmacodynamic Hybrids of Losartan and Its Active Metabolite: Design,Synthesis, and Biopharmacological Properties 157
Glycoconjugated metal complexes as cancer diagnostic and therapeutic agents 154
A Convenient Three-Component Synthesis of Substituted Cyclopentadienyl Tricarbonyl Rhenium Complexes 150
Synthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes 149
Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands 145
Synthesis and Biological Evaluation of New Glycoconjugated LDH Inhibitors as Anticancer Agents 143
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer 143
Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model 142
4-[6-(dansylamino)hexylamino]-7-methyl-2-phenyl-1,8-naphthyridine as a new potential fluorescent probe for studying A1-adenosine receptor 142
First examples of H2S-releasing glycoconjugates: stereoselective synthesis and anticancer activities 141
Anticancer Agents That Counteract Tumor Glycolysis 140
Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands 140
Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds 139
Risks and Benefits Related to Alimentary Exposure to Xenoestrogens 138
A Polymer-Supported Phosphazine as a Stable and Practical Reagent in the Three-Component Synthesis of Substituted (Cyclopentadienyl)tricarbonylrhenium Complexes 137
Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform a (LDH-A) as Starvation Agents against Cancer Cells 137
A Virtual Screening Study for Lactate Dehydrogenase 5 Inhibitors by using a Pharmacophore-Based Approach 137
Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor 137
Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand 136
Phosphonomethylphosphorylmethyl(oxy)-analogues of geranylgeranyl diphosphate as stable and selective geranylgeranyl protein transferase inhibitors 136
Antiproliferative oxime derivatives that inhibit glucose transporter 1 (GLUT1) in cancer cells 135
Estrogen receptor ligands: a patent review update 133
7-Nitrobenzofurazan (NBD)-Derivatives Of 5'-N-Ethylcarboxamidoadenosine (NECA) As New Fluorescent Probes For Human A3 Adenosine Receptors 132
Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer 132
Dual Targeting of the Warburg Effect with a Glucose-Conjugated Lactate Dehydrogenase Inhibitor 131
An update on therapeutic opportunities offered by cancer glycolytic metabolism 130
Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death 130
Systems Structural Biology Analysis of Ligand Effects on ERα Predicts Cellular Response to Environmental Estrogens and Anti-hormone Therapies 130
Sonde diagnostiche per evidenziare all’infrarosso cellule e tessuti affetti da condizioni patologiche o metaboliche 130
NO-Sartans: A New Class of Pharmacodynamic Hybrids as Cardiovascular Drugs 129
Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5 129
METAL SALT-PROMOTED ALDOL REACTION OF SILYL ENOL ETHERS WITH ALDEHYDES 128
Pharmacological study on the cardiovascular activity of no-sartans, pharmacodynamic hybridsexhibiting at1-antagonist and no-donor properties 127
Selective activators of estrogen receptor beta based on the aldoxime and ketoxime scaffolds 127
COMPOUNDS INHIBITING THE ENZYME LACTATE DEHYDROGENASE (LDH), PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 127
CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides 127
Identification of new FYN kinase inhibitors using a FLAP-based approach 126
Reactive Oxygen Species Synergize to Potently and Selectively Induce Cancer Cell Death 126
Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials 123
Synthesis of stable analogues of geranylgeranyl diphosphate possessing a (Z,E,E)-geranylgeranyl side chain, docking analysis, and biological assays for prenyl protein transferase inhibition 122
Tackling tumors by exploiting their glucose avidity and high rate of glycolysis 122
New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2) 121
Design, Synthesis, and Evaluation of GLUT Inhibitors 121
Boronic Acids in the Three-Component Synthesis of Carbon-Substituted Cyclopentadienyl Tricarbonyl Rhenium Complexes 120
Preclinical emergence of novel lactate dehydrogenase inhibitors as potent antitumor agents in hypoxic models of pancreatic cancer: molecular mechanisms underlying their synergistic interaction with gemcitabine 120
Metabolically labile cannabinoid esters: A ‘soft drug’ approach for the development of cannabinoid-based therapeutic drugs 120
Ceramide analogues in apoptosis: a new strategy for anticancer drug development 120
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia 120
Spirocyclic Benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel 120
New Benzopyran-Based Openers of the Mitochondrial ATP-Sensitive Potassium Channel with Potent Anti-Ischemic Properties 119
Small-molecule inhibitors of human LDH5 119
Hypoxia-activated lysyl oxidase (LOX) inhibitors in the treatment of highly invasive and metastatic cancer 118
Cyclic Ketoximes as Estrogen Receptorβ Selective Agonists 118
Synthesis of a Resveratrol Analogue with High Ceramide-Mediated Proapoptotic Activity on Human Breast Cancer Cells 117
Glucose transporters: production, crystallization and inhibition 117
Bioreductively Activated Lysyl Oxidase Inhibitors against Hypoxic Tumours 116
Anticancer agents interacting with membrane glucose transporters 116
Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors 116
Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells 116
New N-n-propyl-substituted 3-Aryl and 3-Cyclohexyl piperidines as partial agonists at the D4 dopamine receptor 115
a) Analgesici "pesanti": i Dramadoli; b) Ombrelli molecolari 114
Heterogeneous Asymmetric Epoxidation of Unfunctionalized Olefins Catalyzed by Polymer-Bound (Salen)manganese Complexes 114
Diaryl-substituted salicyl- and anthranyl-ketoximes as potential estrogen receptor ligands 114
Sulfonamido-derivatives of unsubstituted carbazoles as BACE1 inhibitors 113
Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways 113
Salicylketoximes that target glucose transporter 1 restrict energy supply to lung cancer cells 113
N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation 112
a) Dendrimeri a rilascio controllato di ossido d'azoto; b) Platensimicina: un nuovo antibiotico per un nuovo target 111
Drug-likeness of multiple-binding drugs 110
Radiosensitizing potentialof small organic molecules toward hypoxic tumor cells in the radiotherapy 109
Evaluation of the NO-releasing properties of NO-donor linkers 109
Synthesis and antiviral properties of novel analogues of monophosphate and diphosphate bioactive forms of acyclovir 108
Natural compounds as inhibitors of lactate dehydrogenase 108
Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors 108
a) Arricchimento isotopico con B-10 per migliorare le radioterapie antitumorali di tipo BNCT; b) Antagonisti istaminici anti-H3 a struttura chinazolinica; c) Cannabinoidi non psicotropi ad azione analgesica periferica; d) Blocco selettivo di un canale del sodio: nuova speranza per il dolore neuropatico e infiammatorio? 107
a) Antimalarici ad azione inibitoria sulla farnesilazione proteica nel plasmodio. b) Un "dolce" trattamento anti-rughe per la pelle 107
BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides 107
Triazole-substituted N-hydroxyindol-2-carboxylates as inhibitors of isoform 5 of human lactate dehydrogenase (hLDH5) 107
Antiproliferative activity and cell cycle analysis of 2-(3,5-dihydroxyphenyl)-6-hydroxybenzothiazole on MCF-7 breast and HCT-15 colon cancer cell lines. 107
Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors 107
Abstract 3082: Targeting hypoxic pancreatic cancer cells with glucose conjugated lactate dehydrogenase inhibitor NHI-Glc-2 107
Crystallographic Evidence for the Electronic Distribution in (2,4-Cyclopentadien-1-ylidenehydrazono)triphenylphosphorane 106
Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues 106
A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1 106
Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors 105
Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors 105
Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents 105
Synthesis of aniline-type analogues of farnesyl diphosphate and their biological assays for prenyl protein transferase inhibitory activity 105
Synthesis of heterocycle-based analogs of resveratrol and their antitumor and vasorelaxing properties 104
Structural optimization of 4-chlorobenzoylpiperidine derivatives for the development of potent, reversible and selective monoacylglycerol lipase (MAGL) inhibitors 104
Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer 104
Totale 12.819
Categoria #
all - tutte 55.721
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.721


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.817 0 0 0 0 0 0 0 75 147 620 545 430
2019/20204.414 627 349 574 267 352 436 455 273 349 241 365 126
2020/20212.282 195 119 124 131 237 157 163 236 260 143 151 366
2021/20223.401 116 293 80 199 521 490 129 194 84 120 180 995
2022/20233.973 489 497 260 395 467 506 68 319 625 44 232 71
2023/20242.952 534 449 375 278 506 587 129 94 0 0 0 0
Totale 26.005